What does "peptide dosing" actually mean?
A peptide is a short chain of amino acids — the same building blocks that make proteins. Your body makes thousands of its own peptides; they act as messengers, hormones, and signals. Scientists have learned to manufacture versions of some of these messengers, and a growing number of man-made peptides have been developed as medicines.
Dosing simply means deciding how much to take and when. That sounds simple, but peptide dosing is more complicated than, say, swallowing a tablet, for one key reason: most peptides cannot survive the journey through your stomach. Stomach acid breaks them apart before they can do anything useful. That is why the large majority of peptide medicines are injected, either under the skin (subcutaneous) or into a muscle (intramuscular).
There are two very different categories of peptides people talk about today, and the dosing rules are completely different for each. First, there are FDA-approved peptide medicines — things like semaglutide, tirzepatide, and tesamorelin. These went through years of human clinical trials, and their approved doses are printed on a label that any pharmacist can look up. Second, there are investigational and research peptides — compounds either still being tested in trials or sold online as "for research use only." For these, there is no approved dose, no official label, and no quality-controlled product. The two categories should never be treated the same way.
This guide covers the concepts — what reconstitution is, how units work, what the dosing math looks like — so you can understand the language when a clinician explains a protocol. It is not a how-to for any specific compound.
What is reconstitution — and why does it matter?
Many peptide medicines, especially investigational and research compounds, are stored and shipped as a freeze-dried powder. Freeze-drying (also called lyophilisation) removes almost all the water and pauses the chemistry, which makes the molecule stable for much longer than it would be in liquid form. Before it can be injected, the powder has to be dissolved in water to make a solution. That process is called reconstitution.
Think of it like dissolving a sugar cube in water. The sugar cube is the peptide powder. The water is the liquid you are adding. The resulting syrup is the reconstituted solution, ready to draw into a syringe.
Not just any water will do. Two kinds are used in practice. Sterile water for injection is plain purified water with no additives. It is used once and discarded. Bacteriostatic water for injection — often called BAC water — is the same purified water but with a small amount of benzyl alcohol added. The benzyl alcohol is a preservative. It kills any bacteria that might get in when you push the needle through the stopper, which makes the reconstituted solution safe to use from the same vial multiple times, typically for up to 28 days when stored in a refrigerator.
For most multi-use peptide vials, BAC water is the standard choice. Sterile water is appropriate for single-use situations or where the product label calls for it. Using tap water or any other non-sterile liquid is never appropriate for an injectable solution.
The volume of water added during reconstitution determines the concentration of the solution. Add more water and the concentration goes down; add less and the concentration goes up. That concentration number is what all the dosing math is built on.
How are peptide doses measured?
Peptide doses are almost always measured in milligrams (mg) or micrograms (mcg). These are both units of mass — they describe how much of the actual peptide you are putting in. One milligram is one thousandth of a gram, about the mass of a small grain of sand. One microgram is one millionth of a gram — a thousand times smaller than a milligram.
That thousand-fold gap is the source of one of the most common and dangerous mistakes in peptide dosing: confusing milligrams with micrograms. If a clinician writes a dose in micrograms and you measure it in milligrams, you take a thousand times too much. That is not a rounding error — it is an overdose. If you go the other way, you take a thousand times too little, which is a wasted injection. The units matter enormously.
You may also see the abbreviation IU, which stands for International Unit. IU is a biological activity unit used for some substances — insulin, vitamin D, and natural growth hormone (hGH) are common examples. The size of an IU varies by substance and has no fixed mass equivalent. For most peptide research compounds — BPC-157, CJC-1295, and similar — IU is simply not an applicable unit. There is no validated IU calibration for them. When someone quotes a peptide dose in IU, they are almost always guessing or repeating internet folklore, not referencing a scientific standard.
FDA-approved peptide medicines have clear, unambiguous labelling that specifies the dose in mg, mcg, or mL, the same as any other prescription medicine. The package insert tells you exactly what a milligram looks like in that product. Research compounds have no such label, which is one of the many reasons their "doses" on the internet are unreliable.
| Unit | What it means | Common mistake |
|---|---|---|
| mg (milligram) | 1/1,000 of a gram | Confused with mcg — a 1,000× error |
| mcg (microgram) | 1/1,000,000 of a gram | Confused with mg — a 1,000× error |
| IU (International Unit) | A biological-activity unit (varies by substance) | Applied to peptides that have no IU calibration — not valid |
| mL (millilitre) | The volume you draw into a syringe | Mistaken for the dose itself — it is the volume that carries the dose |
How does reconstitution math work?
Once you know the mass of peptide in a vial and how much water you add, you can calculate the concentration of the resulting solution. Concentration is usually written in mg per mL — milligrams of peptide in each millilitre of solution.
Here is the basic formula: Concentration (mg/mL) = Mass of peptide in vial (mg) ÷ Volume of water added (mL).
To give a conceptual example using a made-up number: suppose a clinician is working with a product that holds 5 mg of peptide in the vial, and they reconstitute it with 2 mL of BAC water. The concentration is 5 ÷ 2 = 2.5 mg/mL. If the dose prescribed is 0.25 mg, you would need 0.25 ÷ 2.5 = 0.1 mL in the syringe.
All of that math can be done by a dosing calculator before a single syringe is filled. The calculator does nothing more than this arithmetic — it does not know what compound you are using, what the right dose is, or whether the compound is approved. It is just a unit-conversion and volume tool. The critical inputs — the right dose, the right concentration, the right compound — come from the prescribing clinician.
It is also worth understanding that the same vial can be reconstituted at different concentrations, which changes the volumes you draw but not the underlying dose. A smaller volume is sometimes preferred to make the injection more comfortable; a larger volume can make very small doses easier to measure accurately. That is a clinical judgement, not a dosing decision you make from a guide.
What kinds of peptides have established doses?
Here the two categories become critical. FDA-approved peptide medicines — a group that now includes more than 80 approved drugs worldwide — have been through rigorous human trials and carry official prescribing information with specific doses. These doses were determined by studying thousands of patients, not by guesswork. When a doctor prescribes semaglutide for weight management, the approved starting dose and titration schedule are specified on the label that the pharmacist dispenses.
Tesamorelin is another example. It is an FDA-approved GHRH (growth hormone-releasing factor) analogue approved for treating excess belly fat in adults with HIV on antiretroviral therapy. In the clinical trial that supported its approval, it reduced visceral fat by about 15 percent compared to placebo over 26 weeks, and that evidence is what earned it the approved label and a specific 2 mg daily dose. There is a real dose for tesamorelin because it was tested, regulated, and approved.
Investigational compounds — those still in clinical trials — have trial protocols, not approved doses. Retatrutide, for example, is a triple-agonist medicine still being evaluated in Phase 3 trials. It has been studied at specific doses within those trials, including once-weekly subcutaneous dosing formats that its long half-life supports. But it is not approved, so it has no prescribing information and no dose outside those supervised research settings.
Research compounds sold online as "for research use only" — things like many peptides available without a prescription — represent the third, least regulated category. For these, animal pharmacokinetic data (how the body handles the compound in rodents or dogs) might exist, but those numbers do not translate into human doses. For example, animal studies of one such compound found an elimination half-life of less than about 30 minutes after injection, but those same studies showed nothing about what dose would be safe or effective in a person. Animal PK is a starting point for further study, not a dosing guide.
The honest summary: for FDA-approved peptides, the dose is on the label. For investigational compounds, it exists only inside a trial. For unapproved research compounds, no validated human dose exists at all. That is not a technicality — it is the actual state of the science.
Why tracking the details matters in practice
Even when a clinician has set a protocol, keeping accurate records is harder than it sounds. A peptide protocol often involves multiple variables at once: the compound, the dose in mg or mcg, the concentration after reconstitution, the syringe volume, the day and time of each injection, and the vial reconstitution date.
That last item — reconstitution date — matters because a reconstituted peptide solution does not stay good indefinitely. BAC water extends the useful life of the solution, typically allowing refrigerated storage for up to several weeks, but after that the potency may degrade. Knowing exactly when you made the solution is essential for knowing when to replace it.
Dosing frequency and timing also matter more than they might seem. Once-weekly medicines like approved GLP-1 receptor agonists are designed to be given on the same day each week. The stable, predictable blood levels they create depend on that regular schedule. Missing a dose or shifting the timing can affect how well the medicine works. Your clinician needs to know if doses were missed, because that information shapes how they adjust your protocol.
Biomarker tracking adds another layer. A clinician following someone on a peptide protocol may monitor bloodwork — things like IGF-1, fasting insulin, liver enzymes, or HbA1c — to check whether the protocol is doing what it is supposed to do, and whether any unexpected changes are happening. Those lab results need to be linked to the protocol timeline to make sense of them. A biomarker result from the sixth week of a protocol means something different from one taken before the protocol started.
All of that — compounds, doses, concentrations, vial dates, injection times, lab values — is the kind of day-to-day information that is easy to track in a structured tool and nearly impossible to keep accurate in a notebook or your head.
Tracking your protocol with PeptidePanel
PeptidePanel is a tracking tool for exactly this kind of detail. It keeps a record of the protocol your clinician set, logs each injection with time and dose, reminds you when your next dose is due, and charts your biomarker results alongside your protocol timeline.
It does not recommend doses, sell peptides, or tell you what to take. Its job is to be the organized notebook that sits between what your clinician prescribed and what actually happened — and to surface that information in a form your clinician can act on.
If your doctor has set a protocol for an FDA-approved medicine, or is supervising a research protocol for an investigational compound, tracking it accurately is part of getting the most out of the clinical relationship. That is the part PeptidePanel handles.